Recursion Pharmaceuticals stock analysis: $197M of cash burned in six months and 28% more shares. Why the model rates RXRX a Sell before its November data.
@2026 – All Right Reserved.
Tag:
Biotechnology
-
-
BiotechnologyUS Stocks
Relay Therapeutics Has Risen Nearly Ninefold on Hopes for Its Lead Drug – the Model Still Rates It Sell
Relay Therapeutics stock analysis: up nearly ninefold on zovegalisib hopes, but with about $10M of revenue and steady losses the model says Sell.
-
BiotechnologyUS Stocks
BeOne Medicines Has Doubled Off Its Low on Brukinsa’s Growth – but at 64 Times Earnings, the Model Stops at Hold
BeOne Medicines stock analysis: Brukinsa drove 29.6% revenue growth and strong margins, but a 64.06 P/E keeps the model’s signal at Hold.
-
BiotechnologyFeaturedUS Stocks
Incyte Grows Revenue 37.7% at a 15.46 P/E – Can It Outrun the 2028 Jakafi Patent Cliff?
Incyte stock analysis: INCY grows revenue 37.7% at a 15.46 P/E with a 98/100 Quality score. Why the model rates it a Buy despite the 2028 Jakafi cliff.
-
BiotechnologyUS Stocks
Faeth Therapeutics Trades Near Its Two-Year High While the Fundamentals Stay Pre-Revenue
Faeth Therapeutics stock analysis: a pre-revenue clinical biotech trading near its two-year high, with no debt, steep losses and a model rating of N/A.
-
BiotechnologyUS Stocks
Madrigal’s Revenue Is Up 71% as Rezdiffra Ramps – the Stock Is Already Near Its Highs
Madrigal Pharmaceuticals stock analysis: 71% revenue growth meets a rich 24x price-to-book near two-year highs. Model signal: Hold.
-
BiotechnologyUS Stocks
IDEAYA Biosciences: Trading Near a Two-Year High While the Model Flags a Sell
IDEAYA Biosciences, Inc. stock analysis: shares sit near a two-year high while a -36.4% gross margin and 25/100 quality score drive a Sell signal.
Newer Posts